AI-Assisted Analysis of the Tumor Microenvironment and PD-L1 Expression in Histiocytic and Dendritic Cell Neoplasms

Project no. 32669 · Status: Kapanmış (Yayın bekleniyor) · 2025

Summary

<p>Histiocytic&nbsp;and&nbsp;dendritic&nbsp;cell&nbsp;neoplasms&nbsp;are&nbsp;rare&nbsp;tumors&nbsp;with&nbsp;heterogeneous&nbsp;biological&nbsp;behavior&nbsp;and&nbsp;an&nbsp;unpredictable&nbsp;prognosis.&nbsp;This&nbsp;study&nbsp;aimed&nbsp;to&nbsp;investigate&nbsp;the&nbsp;prognostic&nbsp;impact&nbsp;of&nbsp;PDL1&nbsp;expression&nbsp;in&nbsp;tumor&nbsp;cells&nbsp;and&nbsp;immune&nbsp;cells,&nbsp;BRAFV600E&nbsp;mutation&nbsp;status,&nbsp;tumor&nbsp;microenvironment&nbsp;features,&nbsp;and&nbsp;various&nbsp;clinicopathological&nbsp;parameters&nbsp;in&nbsp;histiocytic&nbsp;and&nbsp;dendritic&nbsp;cell&nbsp;neoplasms.&nbsp;A&nbsp;total&nbsp;of&nbsp;108&nbsp;cases&nbsp;of&nbsp;histiocytic&nbsp;and&nbsp;dendritic&nbsp;cell&nbsp;neoplasms&nbsp;diagnosed&nbsp;between&nbsp;2006&nbsp;and&nbsp;2025&nbsp;were&nbsp;included.&nbsp;Morphological&nbsp;findings,&nbsp;microenvironmental&nbsp;features,&nbsp;Ki67&nbsp;proliferation&nbsp;index,&nbsp;BRAFV600E&nbsp;mutation&nbsp;status,&nbsp;and&nbsp;PDL1&nbsp;expression&nbsp;were&nbsp;evaluated&nbsp;using&nbsp;cut-off&nbsp;values&nbsp;of&nbsp;5%,&nbsp;10%,&nbsp;20%,&nbsp;and&nbsp;50%.&nbsp;In&nbsp;addition,&nbsp;PDL1&nbsp;expression&nbsp;in&nbsp;tumor&nbsp;cells&nbsp;was&nbsp;assessed&nbsp;by&nbsp;an&nbsp;artificial&nbsp;intelligence-assisted&nbsp;digital&nbsp;analysis&nbsp;method&nbsp;and&nbsp;compared&nbsp;with&nbsp;pathologist-based&nbsp;evaluation.</p><p></p><p>In&nbsp;univariate&nbsp;and&nbsp;multivariate&nbsp;analyses,&nbsp;a&nbsp;high&nbsp;Ki67&nbsp;index,&nbsp;histiocytic&nbsp;atypia,&nbsp;elevated&nbsp;CRP&nbsp;and&nbsp;LDH&nbsp;levels,&nbsp;anemia,&nbsp;high&nbsp;ECOG&nbsp;performance&nbsp;score,&nbsp;advanced&nbsp;Ann&nbsp;Arbor&nbsp;stage,&nbsp;multisystem&nbsp;involvement,&nbsp;bone&nbsp;marrow&nbsp;involvement,&nbsp;and&nbsp;risk-organ&nbsp;involvement&nbsp;were&nbsp;associated&nbsp;with&nbsp;poor&nbsp;prognosis.&nbsp;PDL1&nbsp;expression&nbsp;of&nbsp;≥5%&nbsp;in&nbsp;tumor&nbsp;cells&nbsp;was&nbsp;associated&nbsp;with&nbsp;better&nbsp;overall&nbsp;survival,&nbsp;whereas&nbsp;PDL1&nbsp;expression&nbsp;of&nbsp;≥20%&nbsp;in&nbsp;immune&nbsp;cells&nbsp;was&nbsp;associated&nbsp;with&nbsp;poorer&nbsp;survival.&nbsp;In&nbsp;multivariate&nbsp;analysis,&nbsp;tumor&nbsp;cell&nbsp;PDL1&nbsp;positivity&nbsp;was&nbsp;identified&nbsp;as&nbsp;an&nbsp;independent&nbsp;favorable&nbsp;prognostic&nbsp;factor,&nbsp;while&nbsp;immune&nbsp;cell&nbsp;PDL1&nbsp;positivity&nbsp;and&nbsp;multisystem&nbsp;involvement&nbsp;were&nbsp;identified&nbsp;as&nbsp;independent&nbsp;adverse&nbsp;prognostic&nbsp;markers.&nbsp;In&nbsp;addition,&nbsp;a&nbsp;significant&nbsp;association&nbsp;was&nbsp;demonstrated&nbsp;between&nbsp;tumor&nbsp;cell&nbsp;PDL1&nbsp;expression&nbsp;and&nbsp;BRAFV600E&nbsp;mutation.&nbsp;A&nbsp;strong&nbsp;correlation&nbsp;was&nbsp;observed&nbsp;between&nbsp;pathologist-based&nbsp;and&nbsp;artificial&nbsp;intelligence-assisted&nbsp;scoring&nbsp;methods&nbsp;(r&nbsp;=&nbsp;0.99).&nbsp;Our&nbsp;findings&nbsp;suggest&nbsp;that&nbsp;PDL1&nbsp;has&nbsp;prognostic&nbsp;and&nbsp;potential&nbsp;therapeutic&nbsp;significance&nbsp;in&nbsp;histiocytic&nbsp;and&nbsp;dendritic&nbsp;cell&nbsp;neoplasms.&nbsp;</p>

View details